MedPath

n-3 Fatty Acid Effects in T2DM After Acute High Intensity Exercise

Not Applicable
Completed
Conditions
Type2 Diabetes Mellitus
Interventions
Dietary Supplement: Placebo Group
Dietary Supplement: n-3 PUFA Group
Registration Number
NCT03182712
Lead Sponsor
Federal University of Rio Grande do Sul
Brief Summary

The aim of this study was to verify the effect of a combined supplementation \[n-3 PUFA (known to induce anti-inflammatory effects) plus vitamin E (known for its antioxidant properties)\] on lipidic, glycemic, redox status and inflammatory parameters in type 2 diabetic patients. In addition, considering that exercise, at high intensities, can induce a transient inflammatory state and increase oxidative stress (OS) markers, the investigators tested if our nutritional intervention could attenuate this response within this population (thus, using high intensity exercise as inductor of acute inflammatory/OS state).

Detailed Description

Herein the investigators tested the effect of eight weeks of omega-3 polyunsaturated fatty acid (n-3 PUFA) and vitamin E supplementation before and after an acute high intensity exercise bout on lipid profile, glycemic, redox and inflammatory parameters in type 2 diabetic (T2DM) patients. Thirty T2DM patients, without chronic complications, took part in this study. Blood and urine samples were collected after 12 h-fasting state for baseline biochemical analysis. Thereafter, subjects performed an incremental workload VO2max test on a cycle ergometer to determine the load of the high intensity submaximal exercise. On the following week, blood samples were collected before and immediately after the exercise test for measurements of oxidative stress (OS) and high-sensitivity C-reactive protein (hs-CRP). Afterwards, participants were randomly allocated into two groups: placebo (gelatin) and n-3 PUFA (capsules containing 180 mg of eicosapentaenoic acid, 120 mg of docosahexaenoic acid and 2 mg of vitamin E). Three capsules were ingested daily for eight weeks. Then, the examination protocol and the exercise test were repeated and the samples collected.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Clinical diagnosis of Type 2 Diabetes
  • Male and female
  • Age between 40 and 60 years old.
  • Must be able to do exercise
Exclusion Criteria
  • Smoking;
  • Clinical diagnosis of kidney, pulmonary or heart diseases

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo GroupPlacebo GroupSubjects receiving gelatin capsules (500mg). Three capsules were ingested daily for eight weeks.
n-3 PUFA Groupn-3 PUFA GroupSubjects receiving n-3 PUFA (capsules containing 180 mg of eicosapentaenoic acid, 120 mg of docosahexaenoic acid and 2 mg of vitamin E). Three capsules were ingested daily for eight weeks.
Primary Outcome Measures
NameTimeMethod
Changes on hs-CRP (High-sensitivity C reactive protein)Measured before the supplementation (baseline) and after eight weeks of supplementation

Marker of inflammation expressed in mg/dL

Secondary Outcome Measures
NameTimeMethod
Changes on F2-isoprostanesMeasured before the supplementation (baseline) and after eight weeks of supplementation

Marker of oxidative stress expressed in ng/mL

Changes on Total Antioxidant activityMeasured before the supplementation (baseline) and after eight weeks of supplementation

Marker of oxidative stress expressed in contains per minute

Changes on thiobarbituric acid reactivityMeasured before the supplementation (baseline) and after eight weeks of supplementation

Marker of oxidative stress expressed in nmol/mL

Trial Locations

Locations (1)

Clinical Hospital of Porto Alegre

🇧🇷

Pôrto Alegre, RS, Brazil

© Copyright 2025. All Rights Reserved by MedPath